COMPASS THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
COMPASS THERAPEUTICS, INC. (CMPX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$1.12 thousand for the 12-month period ending 2020-03-31, per its 10-K filed 2020-06-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-06-08
- COMPASS THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was $2.60K, a 1290.91% increase year-over-year.
- COMPASS THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was $262.00, a 88.27% decline year-over-year.
- COMPASS THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $187.00.
- COMPASS THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $2.23K.
- COMPASS THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2020 was -$1.12K, a 123.04% decline from fiscal 2019.
- COMPASS THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $4.87K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-03-31 | $2.60K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08 | $2.86K derived: sum of 2 quarters · filed 2020-06-08 | -$1.12K 10-K · filed 2020-06-08 | |
| 2019-12-31 | $262.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14 | -$3.72K 10-Q · filed 2020-02-14 | ||
| 2019-09-30 | -$3.98K 10-Q · filed 2019-11-13 | |||
| 2019-03-31 | $187.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08 | $2.42K derived: sum of 2 quarters · filed 2020-06-08 | -$2.37K derived: sum of 3 quarters · filed 2020-06-08 | $4.87K 10-K · filed 2020-06-08 |
| 2018-12-31 | $2.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14 | -$2.55K derived: sum of 2 quarters · filed 2020-02-14 | $4.68K 10-Q · filed 2020-02-14 | |
| 2018-09-30 | -$4.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-13 | $2.45K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $7.23K 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |